J & J to enter the robotic surgery market with $3.4B Auris Health buy

Johnson & Johnson (NYSE:JNJ) is stepping into the field of robotic surgery after saying today that its Ethicon subsidiary inked a $3.4 billion deal to pick up surgical robotics pioneer Dr. Fred Moll’s newest robotic surgical play, Auris Health, and its FDA-cleared Monarch platform. The New Brunswick, N.J.-based medtech giant said that the deal will include an additional $2.35 billion in milestone-based contingent payments, bringing the total value of the deal to approximately $5.75 billion. Redwood City, Calif.-based Auris Health’s robotic Monarch platform has FDA clearance for diagnostic and therapeutic bronchoscopic procedures. The system features a controller interface for navigating the integrated flexible robotic endoscope into the periphery of the lung and combines traditional endoscopic views with computer-assisted navigation based on 3D patient models, the company said. In addition to picking up the company and Auris’ FDA-cleared Monarch bronchoscopic-focused robotic platform, Auris CEO and Intuitive Surgical (NSDQ:ISRG) founder Moll will also be coming aboard as part of the acquisition, Johnson & Johnson said. “We’re thrilled to be joining Johnson & Johnson to help push the boundaries of what is possible in medical robotics and improve the lives of patients across the globe. Together, we will be able to dramatically accelerate our collective product innovation to develop new interventional solutions that redefine optimal patient ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Featured Mergers & Acquisitions Robotics Wall Street Beat aurishealth johnsonandjohnson Source Type: news